The transformative nature of our research lies in the detailed study of cell-to-cell communication through direct exchange of small RNA species, including regulatory microRNA. For the past twenty years we have studied the biology of human mesenchymal stem cells and have engineered them to become delivery vehicles to secrete transgene protein products for receptor-mediated uptake by surrounding cells in a damaged tissue or by distant cells through systemic protein production. However in the past two years we have developed new as-yet unpublished data showing that direct transfer of RNA species can occur from the MSC to target cells through direct cell-to- cell communication. Through the use of advanced videomicroscopy and molecular techniques we have determined that this cell-contact-dependent intercellular transfer does not occur through small gap junctions but rather through exosomal transport and direct shuttle of small RNA species through tunneling nanotubules. Mesenchymal stem cells are known to respond rapidly to a damaged, hypoxic or inflamed microenvironment and to support the growth, survival and differentiation of other cell types, including hematopoietic stem cells, cells of the vasculature, neurons and others. This phenomenon has been thought to be almost entirely due to the secretion of extracellular proteins. In contrast, we hypothesize that the control of the fate of target cells by MSC can be also mediated through direct transfer of RNA species. We hypothesize that direct transfer of microRNA from human MSC to target cells is a common mechanism for modulating tissue repair and increasing target cell survival at sites of injury. Our planned studies will use our established xenotransplantation wound model systems to explore this novel, unconventional, and potentially paradigm-shifting hypothesis.
Mesenchymal stem cells/stromal cells (MSC) in many tissues can rescue other cells from damage and death. Our new research shows that they can also influence target cell fate through the direct transfer of small RNA species. Our multidisciplinary research focuses on MSC-mediated microRNA transfer mechanisms and impact on differentiation and repair of target cells including hematopoietic stem cells, cells of the vasculature, and neurons. There is direct relevance to a broad range of diseases.
|Duong, Connie; Yoshida, Sakiko; Chen, Cathy et al. (2017) Novel targeted therapy for neuroblastoma: silencing the MXD3 gene using siRNA. Pediatr Res 82:527-535|
|Park, Susanna S; Moisseiev, Elad; Bauer, Gerhard et al. (2017) Advances in bone marrow stem cell therapy for retinal dysfunction. Prog Retin Eye Res 56:148-165|
|Moisseiev, Elad; Smit-McBride, Zeljka; Oltjen, Sharon et al. (2016) Intravitreal Administration of Human Bone Marrow CD34+ Stem Cells in a Murine Model of Retinal Degeneration. Invest Ophthalmol Vis Sci 57:4125-35|
|Fink, Kyle D; Deng, Peter; Gutierrez, Josh et al. (2016) Allele-Specific Reduction of the Mutant Huntingtin Allele Using Transcription Activator-Like Effectors in Human Huntington's Disease Fibroblasts. Cell Transplant 25:677-86|
|Lakatos, Kinga; Kalomoiris, Stefanos; Merkely, Béla et al. (2016) Mesenchymal Stem Cells Respond to Hypoxia by Increasing Diacylglycerols. J Cell Biochem 117:300-7|
|Nolta, Jan A (2016) ""Next-generation"" mesenchymal stem or stromal cells for the in vivo delivery of bioactive factors: progressing toward the clinic. Transfusion 56:15S-7S|
|Beegle, Julie R; Magner, Nataly Lessa; Kalomoiris, Stefanos et al. (2016) Preclinical evaluation of mesenchymal stem cells overexpressing VEGF to treat critical limb ischemia. Mol Ther Methods Clin Dev 3:16053|
|Jung, Yunjoon; Nolta, Jan A (2016) BMI1 Regulation of Self-Renewal and Multipotency in Human Mesenchymal Stem Cells. Curr Stem Cell Res Ther 11:131-40|
|Pollock, Kari; Dahlenburg, Heather; Nelson, Haley et al. (2016) Human Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-derived Neurotrophic Factor Improve Outcomes in Huntington's Disease Mouse Models. Mol Ther 24:965-77|
|Deng, Peter; Anderson, Johnathon D; Yu, Abigail S et al. (2016) Engineered BDNF producing cells as a potential treatment for neurologic disease. Expert Opin Biol Ther 16:1025-33|
Showing the most recent 10 out of 30 publications